Li Lin, Wang Tianzheng, He Chiyi, Niu Xiaoping
Departments of Gastroenterology, Yijishan Hospital (The First Affiliated Hospital of Wannan Medical College), Wuhu, 241001, P.R. China.
BMC Gastroenterol. 2025 Mar 31;25(1):212. doi: 10.1186/s12876-025-03779-1.
To evaluate the value of the modified Asia-Pacific colorectal cancer screening (APCS) scoring system combined with fecal occult blood test (FOBT) for colorectal cancer (CRC) screening in asymptomatic population of Wannan region.
We prospectively collected and investigated asymptomatic individuals attending Yijishan Hospital (the first affiliated hospital of Wannan Medical College) from January 1, 2021 to December 31, 2022. All enrolled patients received modified APCS scores and FOBT before colonoscopy. We used receiver operating characteristic (ROC) curves to estimate the screening value of the modified APCS score combined with FOBT. We also retrospectively collected patients with stage T1 CRC to explore the independent risk factors for lymph node metastasis (LNM) of CRC.
513 participants were finally included in the study. The combined detection of modified APCS score and FOBT can be divided into 5 groups [modified APCS high risk &FOBT + (T1 group), modified APCS high risk &FOBT- (T2 group), modified APCS medium risk &FOBT + (T3 group), modified APCS medium risk &FOBT- (T4 group), and modified APCS low risk &FOBT- (T5 group)], the detection rates of CRC were 9.09%, 1.67%, 5.77%, 0.92% and 0%, respectively. The detection rate of advanced adenoma was 25.76%, 35.00%, 21.15%, 2.75% and 1.96%, respectively. The detection rate of CRC in T1 group was 9.88 times that in T4 group, and the detection rate of advanced adenoma was 9.36 times that in T4 group. The high-risk group and positive rate of modified APCS were indicators for further colonoscopy. Tumor gross morphology, tumor differentiation degree, and nerve infiltration were independent risk factors for T1 CRC LNM.
The combination of modified APCS score and FOBT test has important clinical application value in the preliminary screening of colorectal tumors in asymptomatic population. For selected T1 CRC patients, if the lesion is ulcerative and the pathology indicates low differentiation, endoscopic submucosal dissection (ESD) treatment should be carefully selected to prevent the risk of LNM.
评估改良亚太结直肠癌筛查(APCS)评分系统联合粪便潜血试验(FOBT)在皖南地区无症状人群中进行结直肠癌(CRC)筛查的价值。
前瞻性收集并调查2021年1月1日至2022年12月31日在皖南医学院第一附属医院弋矶山医院就诊的无症状个体。所有纳入患者在结肠镜检查前接受改良APCS评分和FOBT。我们使用受试者操作特征(ROC)曲线来评估改良APCS评分联合FOBT的筛查价值。我们还回顾性收集了T1期CRC患者,以探讨CRC淋巴结转移(LNM)的独立危险因素。
最终纳入513名参与者。改良APCS评分与FOBT联合检测可分为5组[改良APCS高风险&FOBT+(T1组)、改良APCS高风险&FOBT-(T2组)、改良APCS中风险&FOBT+(T3组)、改良APCS中风险&FOBT-(T4组)、改良APCS低风险&FOBT-(T5组)],CRC的检出率分别为9.09%、1.67%、5.77%、0.92%和0%。高级别腺瘤的检出率分别为25.76%、35.00%、21.15%、2.75%和1.96%。T1组CRC的检出率是T4组的9.88倍,高级别腺瘤的检出率是T4组的9.36倍。改良APCS的高风险组和阳性率是进一步行结肠镜检查的指标。肿瘤大体形态、肿瘤分化程度和神经浸润是T1期CRC发生LNM的独立危险因素。
改良APCS评分与FOBT检测联合在无症状人群结直肠肿瘤的初筛中有重要临床应用价值。对于选定的T1期CRC患者,如果病变为溃疡性且病理提示低分化,应谨慎选择内镜黏膜下剥离术(ESD)治疗以预防LNM风险。